Measurement of adiponectin production from differentiated metabolic stem cells

• Published in: Hormone and metabolic research Vol. 42; no. 5; p. 318
• Main Authors: Inomata-Kurashiki, Y, Maeda, K, Yoshioka, E, Fukuhara, A, Imagawa, A, Otsuki, M, Shimomura, I
• Format: Journal Article
• Language: English
• Published: Germany 01-05-2010
• Subjects: Adipocytes - drug effects; Adipocytes - metabolism; Adiponectin - biosynthesis; Adiponectin - genetics; Adult; Aged; Aged, 80 and over; Cell Differentiation - physiology; Cells, Cultured; Female; Glucose Transporter Type 4 - biosynthesis; Glucose Transporter Type 4 - genetics; Humans; Male; Metabolic Syndrome - metabolism; Middle Aged; PPAR gamma - genetics; Reverse Transcriptase Polymerase Chain Reaction; RNA - biosynthesis; RNA - isolation & purification; Stem Cells - drug effects; Stem Cells - metabolism
• ISSN: 1439-4286
• DOI: 10.1055/s-0030-1248304

To treat metabolic syndrome, fat tissue dysfunction should be corrected rather than controlling conventional risk factors such as hypertension, dyslipidemia, and diabetes mellitus. For this purpose, accumulating evidence suggests increasing plasma adiponectin levels can be a key treatment strategy, especially in setting of food or drug selection. Here we report that adipocyte precursors obtained from several sites of fat tissue, which we call Metabolic Stem Cells (MSC), could be used as a novel screening system to identify adiponectin enhancing drugs or food for individual patients. MSC were prepared from fat tissues collected from 29 patients. They were differentiated in cultures into mature adipocytes. The time course of adiponectin production was independent of the number of mature adipocytes and gradually decreased at 48 h after differentiation. Pioglitazone, a full PPARgamma agonist, stabilized adiponectin production at days 8-16 after differentiation, whereas telmisartan, a partial PPARgamma agonist, showed variable response. Dividing the adiponectin secretion of day 12 by that of day 10 provided an estimate of adiponectin-producing activity irrespective of the number of MSC-derived adipocytes in culture. Using this score of adiponectin-production activity, we successfully assessed 16 agents in a 96-well plate. The effect of each agent on adiponectin production showed a similar pattern, independent of the site of isolated adipose tissue. Our results show that MSC can be used as a tool for selecting drugs that enhance adiponectin-production activity.